In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
Professor John Zalcberg OAM Australian Clinical Trials Alliance (ACTA) Board Director & former ACTA Board Chair
Shanny Dyer, Chief Executive Officer, ARCS Australia
Leanne Wells, Chief Executive Officer, Consumers Health Forum of Australia
Liz de Somer, Chief Executive Officer Medicines Australia
Ian Burgess, Chief Executive Officer,
Medical Technology Association of Australia
Watch Season 5, Australian Health Journal Episode S5E1
-
Expansion of specialist training in regional & rural areas
Associate Professor Sanjay Jeganathan, Chair of the Council of Presidents of Medical Colleges (CPMC) states, ”Our rural and regional communities deserve the same access to specialist care as our cities. We’re seeing real results from our colleges’ commitment to rural training.”
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
